Best Practices

But study shows risk was better than expected-so expanded-criteria organs might be 'only marginally worse' than standard

But oral therapy associated with more frequent adverse events

Study shows it's safe and can desensitize, but response range is wide

Real-world outcomes with investigational drug still favourable

The new drug safinamide might have some impact in preventing the involuntary movements characteristic of Parkinson's disease. However, it did not perform any better than placebo over a two-year period.

Innovation and improving productivity are key to improving health systems around the world, but especially here in Canada, according to Anne Snowdon, the Ivey Centre for Health Innovation and Leadership’s newly appointed chair.

NIH puts an early end to its trial of combination cholesterol therapy

Tolerating heated milk a positive prognostic sign for becoming tolerant to all milk products